NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









LynxDx

LynxDx

Private
Ann Arbor, MichiganHealthcare & Life Scienceshttps://www.lynxdx.com/

Last Round

Grant

Sep 1, 2020

Total Funding Raised

$3.95M

Company Overview

LynxDx is a biotechnology company that develops innovative diagnostic solutions, including the MyProstateScore (MPS) urine test for prostate cancer risk assessment.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

prostate cancer screeninggenomic diagnostic testliquid biopsyMyProstateScoreMPSnon-invasive diagnosticsprostate cancer risk assessmentprecision medicinebiomarker testurology diagnosticsactive surveillancepredictive algorithmclinical laboratorydiagnostic assay

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

LynxDx Comparables

Compare LynxDx with similar companies based on industry and business-model similarity.

LynxDx comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MiRNA Scientific
86%
NucleoBio Corp
83%
MDxHealth
80%

LynxDx Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 1, 2020
GrantJun 15, 2020
SeedJan 1, 2020
GrantSep 23, 2019

Key People

Founding team and executive leadership

Jeff Crays

Chief Technology Officer

Executive Team

Mark Willig

Advisory Board Member and Chief Commercial Officer (CCO)

Executive Team

LynxDx Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 5, 2026

    Monthly visitors increased 81% MoM, reaching 8.5K.

  • Jun 15, 2020

    $2M grant from National Cancer Institute and NIH.

LynxDx Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

LynxDx Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about LynxDx's valuation, stock price, and market status.

Firmographic Details

HeadquartersAnn Arbor, Michigan
Employee Range87
Year Founded2019
Last FundingSep 1, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.